Olaparib combined with paclitaxel has previously shown a significant improvement in overall survival versus placebo plus paclitaxel as second-line therapy in a phase 2 study in Asian patients with advanced gastric cancer, especially in those with ataxia-telangiectasia mutated protein (ATM)-negative tumours. Here, we report the primary efficacy and safety analyses from a subsequent phase 3 trial.

中文翻译：

---

一线治疗（GOLD）后进展的晚期胃癌患者，奥拉帕利联合紫杉醇：一项双盲，随机，安慰剂对照的3期临床试验。

在亚洲晚期胃癌患者，尤其是共济失调-毛细血管扩张突变蛋白（ATM）阴性肿瘤的亚洲患者的第二阶段研究中，奥拉帕利联合紫杉醇作为二线治疗的总生存率较安慰剂加紫杉醇显着提高。在这里，我们报告了后续3期试验的主要功效和安全性分析。